The Oncoematology Working Group will generate tools to improve molecular classification, risk assessment and design of personalized therapies in patients with hematological malignancies. The WG is coordinated by Pier Giuseppe Pelicci (IEO) and currently includes collaborators from other 16 IRCCS.
The first objective of the WG is to evaluation the risk of secondary leukemias in cancer survivors (therapy related leukemias). These diseases represent an increasing clinical problem, given that the population is aging and oncological therapies are improving. Therapy related leukemias are often not diagnosed or diagnosed too late, are frequent, and represent a challenge for the survival and quality of life of individuals who have recovered from cancer.
Specifically, the use of genetic panels will define the predictive value of the following factors in the development of therapy related leukemias:
- Genetic alterations in the germ line (hereditary variants);
- Accumulation of DNA damage following chemotherapy;
- Clonal hematopoiesis at different time intervals before and after chemotherapy (i.e. the presence in the peripheral blood of healthy individuals of clonal populations of cells with somatic mutations in genes associated with hematological malignancies)
- Interaction between germline and somatic mutations.
The WG is also validating ultra-sensitive gene panels for monitoring minimal residual disease and high-density panels for diagnostic and therapeutic stratification.
- Secretary (of the Executive Board): Pier Giuseppe Pelicci - IEO MILAN